Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets;Modulation de l'immunosuppression par des chimiothérapies et identification de nouvelles cibles thérapeutiques

Bulletin du Cancer

Volumn 101, Issue 6, 2014, Pages 605-607

  Bruchard, Mélanie ^a   Ghiringhelli, François ^a,b  

^a Chu   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Chemoresistant tumor; Inflammasome; Myeloid cells

Indexed keywords

CATHEPSIN B; CRYOPYRIN; FLUOROURACIL; GEMCITABINE; IMMUNOSUPPRESSIVE AGENT; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 1BETA;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; PROTEIN PROTEIN INTERACTION; REVIEW; SUPPRESSOR CELL; TUMOR GROWTH;

CHEMORESISTANT TUMOR; INFLAMMASOME; MYELOID CELLS;

ANIMALS; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; DEOXYCYTIDINE; EPOXY COMPOUNDS; FLUOROURACIL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMASOMES; INTERLEUKIN-17; INTERLEUKIN-1BETA; MICE; MYELOID CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TYROSINE;

EID: 84905120828     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2014.1936     Document Type: Article

References (5)

1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31 : 51-72.
2. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30 : 61-9.
3. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34 : 336-44. (Pubitemid 39255944)
4. Bruchard M, Mignot G, Derangere V, et al. Chemotherapytriggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19 : 57-64.
5. Chung AS, Wu X, Zhuang G, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19 : 1114-23.